Moderna Q4 2024 Earnings Report
Key Takeaways
Moderna reported a sharp year-over-year revenue decline in Q4 2024, primarily driven by reduced demand for its COVID-19 vaccine. The company posted a substantial net loss and negative operating income, reflecting restructuring costs and lower sales volumes. Despite these challenges, Moderna continued advancing its late-stage pipeline and cost-cutting initiatives.
Revenue fell by 64.48% YoY due to lower COVID-19 vaccine sales.
The company reported a net loss of $1.12 billion compared to a net income of $217 million in Q4 2023.
Operating margin turned negative, driven by restructuring costs and lower sales volumes.
Moderna is focusing on pipeline expansion and cost efficiency to improve future performance.
Moderna Revenue
Moderna EPS
Moderna Revenue by Segment
Moderna Revenue by Geographic Location
Forward Guidance
Moderna expects 2025 revenue between $1.5 billion and $2.5 billion, with a strong focus on pipeline expansion and cost efficiency.
Positive Outlook
- Pipeline expansion with up to 10 product approvals expected by 2027.
- Regulatory filings for next-gen COVID-19, RSV, and flu/COVID combo vaccines.
- Cost reduction initiatives expected to remove nearly $1 billion in expenses.
- Cash balance projected to remain strong at approximately $6 billion by year-end.
- Focus on operational efficiencies and restructuring to optimize financial performance.
Challenges Ahead
- Continued revenue decline expected due to lower COVID-19 vaccine sales.
- High R&D expenses will continue due to ongoing late-stage trials.
- Operating losses may persist until new product approvals drive revenue growth.
- Competitive pressures in the COVID-19 and respiratory vaccine markets.
- Market uncertainty regarding demand for future vaccines.